PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number

3

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

10/748831-Conf. #2793 Filing Date December 30, 2003 First Named Inventor Richard L. BOYD Art Unit 1623 Examiner Name Not Yet Assigned Attorney Docket Number 0286336.00155US1/NOR-016CP2

			· 		
ENCLOSURES (Check all that apply)					
Fee Transmittal Form	Drawing(s)		After Allowance Communication to TC		
Fee Attached	Licensing-related	d Papers	Appeal Communication to Board of Appeals and Interferences		
Amendment/Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Final	Petition to Conve Provisional Appli		Proprietary Information		
Affidavits/declarate	ion(s) Power of Attorney Change of Corres	r, Revocation pondence Address	Status Letter		
Extension of Time Requ	uest Terminal Disclain	ner	X Other Enclosure(s) (please Identify below):		
Express Abandonment	Request Request for Ref	und	Return Receipt Postcard		
Supplemental Information Disclosure Statement	on CD, Number of C	CD(s)			
Certified Copy of Priority Document(s)	Landscape	Table on CD			
Reply to Missing Parts/ Incomplete Application	Remarks				
Reply to Missing I 37 CFR 1.52 or 1.					
	SIGNATURE OF APPLICANT	, ATTORNEY, OR A	GENT		
WILMER CUTLER PICKERING HALE AND DORR LLP					
Signature Quo kaleike Kelin					
I Printed name	se Kerner, Ph.D.				
Date June 22,	2006	Reg. No.	33,523		

I hereby certify that this paper (along with	any paper referred to	as being attached or e	nclosed) is being depor	sited with the U.S. Postal Service or
the date shown below with sufficient post	age as First Class Mai	, in an envelope addre	ssed to: Commissione	r for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450.	11 1		,	

Dated: June 22, 2006

Signature Atgranus Large (Stephanic R. Douglas)



I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313_1451.

Dated: June 22, 2006

Signature (Stephanie R. Douglas)

Docket No.: 0286336.00155US1/NOR-016CP2

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Richard L. BOYD

Confirmation No.:

2793

Application No.:

10/748831

Art Unit:

1623

Filed:

December 30, 2003

Examiner:

Not Yet Assigned

Title:

HEMATOPOIETIC STEM CELL GENE THERAPY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. No fee is required.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Respectfully submitted,

Dated: June 22, 2006

Ann-Louise Kerner, Ph.D. Registration No.: 33,523

ala-Louise teta

Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109 (617) 526-6000 (telephone) (617) 526-5000 (facsimile)

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subs	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/748831-Conf. #2793	
IN	IFORMATION	N DI	SCLOSURE	Filing Date	December 30, 2003	
S	STATEMENT BY APPLICANT			First Named Inventor	Richard L. BOYD	
			Art Unit	1623		
	(Use as many sh	heets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	0286336.00155US1/NOR-016CP2	

	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	I TABLIC OF FAIGHTEE OF	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-4,049,805	09-20-1977	Strade	
	AB*	US-5,759,551	06-02-1998	Ladd et al.	

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T٩	
	BA	EP-0882736A1	12-09-1998	LABORATORIE THERAMEX,			
				S.A.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	CA	Gojo et al., Gene Therapy and Transplantation, (2000), Vol. 69, pp. 1-9.			
	СВ	Ross et al., "Gene Therapy in the United States: A Five-Year Status Report," Human Gene Therapy, 1996, pp. 1781-1790, Vol. 7.			
	CC	Belhadj et al., "Hepatosplenic gamma-delta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report of a Series of 21 Patients," Blood, 2003, pp. 4261-4269, Vol. 102.			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered

¹Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.